Valuation: Vertex Pharmaceuticals Incorporated

Market Cap 133B 115B 108B 98.3B 185B 12,672B 188B 1,264B 495B 6,336B 499B 488B 21,149B P/E 2026 *
30.9x
P/E 2027 * 25.4x
Enterprise Value 119B 103B 96.15B 87.76B 165B 11,313B 168B 1,128B 442B 5,657B 445B 435B 18,881B EV / Sales 2026 *
8.99x
EV / Sales 2027 * 7.84x
Free-Float
99.79%
Yield 2026 *
-
Yield 2027 * -
1 day+1.10%
1 week+12.52%
Current month+11.01%
1 month+9.12%
3 months+23.23%
6 months+14.28%
Current year+16.83%
1 week 479.02
Extreme 479.02
546.17
1 month 465
Extreme 465
546.17
Current year 412.27
Extreme 412.27
546.17
1 year 374.17
Extreme 374.17
546.17
3 years 340.83
Extreme 340.83
546.17
5 years 176.36
Extreme 176.36
546.17
10 years 71.46
Extreme 71.46
546.17
Manager TitleAgeSince
Chief Executive Officer 53 31/03/2020
Director of Finance/CFO 57 09/04/2019
Chief Tech/Sci/R&D Officer - 29/02/2024
Director TitleAgeSince
Director/Board Member 66 31/12/1997
Chairman 70 30/04/2012
Director/Board Member 57 17/06/2015
Date Insider Type Main position Quantity % Market Cap.
21/07/26 Free

General Counsel

8,251 0.0033%
21/07/26 Free

Public Communications Manager

8,251 0.0033%
15/07/26 Free

Director

100 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+1.10%+12.52%+44.50%+52.47% 133B
-1.37%+8.35%+94.20%+133.06% 1,098B
-0.77%+2.12%+49.89%+50.90% 631B
+0.85%+2.04%+26.28%+65.14% 438B
-1.13%+3.62%+49.72%+38.22% 368B
-0.74%+1.09%+33.81%+38.95% 298B
-1.22%+2.99%+8.44%+6.11% 251B
-0.70%+9.35%+43.74%+58.09% 226B
+0.34%+1.62%-4.91%-50.77% 209B
+2.04%+3.52%+13.70%+69.71% 165B
Average +0.12%+1,540.84%+35.94%+46.19% 381.71B
Weighted average by Cap. +0.13%+1,302.35%+50.81%+66.78%

Financials

2026 *2027 *
Net sales 13.19B 11.43B 10.7B 9.76B 18.36B 1,259B 18.67B 126B 49.12B 629B 49.52B 48.44B 2,101B 14.58B 12.64B 11.83B 10.8B 20.3B 1,392B 20.65B 139B 54.32B 696B 54.76B 53.56B 2,323B
Net income 4.32B 3.74B 3.5B 3.2B 6.01B 412B 6.11B 41.08B 16.08B 206B 16.21B 15.85B 687B 5.21B 4.52B 4.23B 3.86B 7.26B 498B 7.38B 49.62B 19.42B 249B 19.58B 19.15B 830B
Net Debt -14.24B -12.34B -11.55B -10.54B -19.83B -1,359B -20.16B -136B -53.04B -680B -53.47B -52.3B -2,268B -18.44B -15.97B -14.95B -13.65B -25.67B -1,759B -26.1B -175B -68.67B -880B -69.23B -67.71B -2,936B
Logo Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (62.9%), Europe (28.8%) and other (8.3%).
Employees
6,400
Date Price Change Volume
11/08/26 US$529.65 +1.10% 1,064,571
10/08/26 US$523.91 +5.61% 2,682,319
07/08/26 US$496.07 +2.49% 992,491
06/08/26 US$484.03 -0.17% 1,015,131
05/08/26 US$484.83 +1.28% 1,383,067
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
529.65USD
Average target price
563.12USD
Spread / Average Target
+6.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VRTX Stock